XOMA Corporation (NASDAQ:XOMA) CEO James R. Neal sold 11,568 shares of XOMA Corporation stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $30.83, for a total transaction of $356,641.44. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
James R. Neal also recently made the following trade(s):
- On Wednesday, November 15th, James R. Neal sold 46,296 shares of XOMA Corporation stock. The shares were sold at an average price of $28.24, for a total transaction of $1,307,399.04.
XOMA Corporation (NASDAQ:XOMA) opened at $22.90 on Friday. XOMA Corporation has a 12-month low of $3.96 and a 12-month high of $33.00. The company has a quick ratio of 3.45, a current ratio of 3.45 and a debt-to-equity ratio of 3.53.
XOMA has been the topic of a number of research reports. Zacks Investment Research raised shares of XOMA Corporation from a “sell” rating to a “buy” rating and set a $25.00 target price on the stock in a research note on Tuesday, October 17th. HC Wainwright reissued a “buy” rating and set a $38.00 price target on shares of XOMA Corporation in a research report on Tuesday, October 17th. Finally, Wedbush reissued a “hold” rating on shares of XOMA Corporation in a research report on Monday, August 14th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. XOMA Corporation presently has a consensus rating of “Buy” and a consensus target price of $30.00.
XOMA Corporation Company Profile
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
Receive News & Ratings for XOMA Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Corporation and related companies with MarketBeat.com's FREE daily email newsletter.